Fursultiamine/ja: Difference between revisions
Fursultiamine/ja
Updating to match new version of source page |
Created page with "<!--Pharmacokinetic data--> | bioavailability = | metabolism = | elimination_half-life = | excretion =" Tags: Mobile edit Mobile web edit |
||
| Line 1: | Line 1: | ||
<languages /> | <languages /> | ||
{{Drugbox | {{Drugbox | ||
| IUPAC_name = ''N''-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-''N''-<nowiki>{</nowiki>(1''E'')-4-hydroxy-1-methyl-2-[(tetrahydrofuran-2-ylmethyl)disulfanyl]but-1-en-1-yl}formamide | | IUPAC_name = ''N''-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-''N''-<nowiki>{</nowiki>(1''E'')-4-hydroxy-1-methyl-2-[(tetrahydrofuran-2-ylmethyl)disulfanyl]but-1-en-1-yl}formamide | ||
| image = Fursultiamine.png | | image = Fursultiamine.png | ||
| alt = | | alt = フルスルチアミンの骨格式 | ||
| width = 200 | | width = 200 | ||
| image2 = Fursultiamine 3D ball.png | | image2 = Fursultiamine 3D ball.png | ||
| alt2 = | | alt2 = フルスルチアミン分子のボール＆スティックモデル | ||
| width2 = 200 | | width2 = 200 | ||
<!--Clinical data--> | <!--Clinical data--> | ||
| tradename = | | tradename = | ||
| Line 19: | Line 15: | ||
| legal_status = otc | | legal_status = otc | ||
| routes_of_administration = [[Mouth|Oral]] | | routes_of_administration = [[Mouth|Oral]] | ||
<!--Pharmacokinetic data--> | <!--Pharmacokinetic data--> | ||
| bioavailability = | | bioavailability = | ||
| Line 27: | Line 21: | ||
| elimination_half-life = | | elimination_half-life = | ||
| excretion = | | excretion = | ||
<!--Identifiers--> | <!--Identifiers--> | ||
| CAS_number = 804-30-8 | | CAS_number = 804-30-8 | ||
| Line 41: | Line 33: | ||
| UNII_Ref = {{fdacite|correct|FDA}} | | UNII_Ref = {{fdacite|correct|FDA}} | ||
| UNII = 05J61265PX | | UNII = 05J61265PX | ||
<!--Chemical data--> | <!--Chemical data--> | ||
| C=17 | H=26 | N=4 | O=3 | S=2 | | C=17 | H=26 | N=4 | O=3 | S=2 | ||
| smiles = O=CN(\C(=C(\SSCC1OCCC1)CCO)C)Cc2cnc(nc2N)C | | smiles = O=CN(\C(=C(\SSCC1OCCC1)CCO)C)Cc2cnc(nc2N)C | ||
}} | }} | ||
<div lang="en" dir="ltr" class="mw-content-ltr"> | <div lang="en" dir="ltr" class="mw-content-ltr"> | ||
Revision as of 09:41, 3 April 2024
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C17H26N4O3S2 |
| Molar mass | 398.54 g·mol−1 |
| 3D model (JSmol) | |
| |
Fursultiamine (INN; chemical name thiamine tetrahydrofurfuryl disulfide or TTFD; brand names Adventan, Alinamin-F, Benlipoid, Bevitol Lipophil, Judolor, Lipothiamine) is a medication and vitamin used to treat thiamine deficiency. Chemically, it is a disulfide derivative of thiamine and is similar in structure to allithiamine.
It was synthesized in Japan in the 1960s from allithiamine for the purpose of developing forms of thiamine with improved lipophilicity for treating vitamin B1 deficiency (i.e., beriberi), It was subsequently commercialized not only in Japan but also in Spain, Austria, Germany, and the United States.
See also
Further reading
- Lonsdale D (September 2004). "Thiamine tetrahydrofurfuryl disulfide: a little known therapeutic agent". Medical Science Monitor. 10 (9): RA199–203. PMID 15328496.
 | この記事は、クリエイティブ・コモンズ・表示・継承ライセンス3.0のもとで公表されたウィキペディアの項目Fursultiamine/ja(6 April 2023編集記事参照)を素材として二次利用しています。 Lua error in Module:Itemnumber at line 91: attempt to concatenate local 'qid' (a nil value). |